comparemela.com
  1. Home
  2. Live Updates
  3. Trial Identifier - Breaking News

Latest Breaking News On - Trial identifier - Page 6 : comparemela.com

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U S IDE Trial

/PRNewswire/ atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today.

United statesSept occluderLaurent grandidierKatie arnoldUniversity of virginiaCompany data on fileScott limDevice exemptionTrial identifierHeart medicalAtheart medical

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U S IDE Trial

/PRNewswire/ atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today.

United statesSept occluderLaurent grandidierKatie arnoldUniversity of virginiaCompany data on fileHeart medicalDevice exemptionScott limTrial identifierAtheart medical

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U S IDE Trial

/PRNewswire/ atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today.

United statesSept occluderLaurent grandidierKatie arnoldUniversity of virginiaCompany data on fileHeart medicalDevice exemptionScott limTrial identifierAtheart medical

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

/PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative.

Jason ehrlichVictor perlrothDevelopment officerKodiak sciences incKodiak sciencesChief medicalChief executive officerAntibody biopolymer conjugateTrial identifierTrial identifiersPalo altoKodiak sciences incHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/  Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat. | February 3, 2022

Jason ehrlichVictor perlrothExchange commissionDevelopment officerKodiak sciencesSecurities exchangeKodiak sciences incChief medicalChief executive officerAntibody biopolymer conjugateTrial identifierTrial identifiersPalo altoSecurities actSecurities exchange actPrivate securities litigation reform act

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.